Skip to main content
Clinical Trials/DRKS00013197
DRKS00013197Recruiting未知

PRIMAL Clinical Study: Efficacy of probiotics to prevent gut dysbiosis in very preterm infants (VPIs) and moderate preterm infants of 28+0 – 32+6 weeks of gestation: A randomized, placebo-controlled double-blind study - primalstudy

niversitätsklinikum Schleswig-Holstein0 sites654 target enrollmentStarted: March 23, 2018Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor
Enrollment
654

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized controlled study
Masking
Blinded (masking used)

Eligibility Criteria

Ages
28 Pregnancy to 32 Pregnancy (—)
Sex
All

Inclusion Criteria

  • Key inclusion criteria for participating in the PRIMAL trial in the first 48 hours of life are:
  • 1. Patients (or as appropriate whose legal guardian) have been informed about the study procedures and interventions and have given written informed consent; 2. Female or male preterm infants born between 28 0/7 to 32 6/7 gestational weeks of any ethnic background, who are admitted to of the listed study sites within the first 48h of life.

Exclusion Criteria

  • 1. Infants with lethal malformations or severe gastrointestinal malformations, which preclude appropriate enteral feeding or require surgery within the primary observational time of 28 days. 2. Infants who primarily present with NEC (Bell´s stage = 1B) or with any medical condition that is likely to be lethal in the first 48 h of life.

Investigators

Sponsor
niversitätsklinikum Schleswig-Holstein

Similar Trials